Τα τελευταία χρόνια έρευνες υποδεικνύουν το πόσο σημαντικά είναι τα προβιοτικά για την υγεία
του ανθρώπου. Μεγάλη επίσης έμφαση έχει δοθεί για την έξτρα χορήγηση
προβιοτικών μέσω συμπληρωμάτων, ακόμα και στα παιδιά!
Τι ακριβώς όμως
είναι τα προβιοτικά;
Τα προβιοτικά
είναι «ζωντανοί μικροοργανισμοί», οι οποίοι όταν χορηγούνται σε επαρκείς
ποσότητες, προσφέρουν βελτίωση στην υγεία και μείωση της πιθανότητας ασθένειας,
μέσω της βελτίωσης της ισορροπίας της εντερικής χλωρίδας, του ατόμου που τα
λαμβάνει. Λέγοντας προβιοτικά προϊόντα εννοούμε τροφές ή διατροφικά
συμπληρώματα τα οποία περιέχουν προβιοτικά συστατικά.
Η σημασία τους είναι μεγάλη, αν σκεφτείτε για παράδειγμα ότι το 80% του ανοσοποιητικού μας συστήματος έγκειται στο πεπτικό μας σύστημα!
Η σημασία τους είναι μεγάλη, αν σκεφτείτε για παράδειγμα ότι το 80% του ανοσοποιητικού μας συστήματος έγκειται στο πεπτικό μας σύστημα!
Γιατί είναι
σημαντικά τα προβιοτικά στην παιδική ηλικία;
Επειδή δρουν
θετικά σε πολλά, όπως:
- Στις
αλλεργίες
- Στην απορρόφηση θρεπτικών συστατικών από την τροφή
- Στη δυσλειτουργία του πεπτικού συστήματος (διάρροια, δυσκοιλιότητα)
- Στα φλεγμονώδη νοσήματα του εντέρου (νόσος crohn)
- Στους κολικούς
- Στις γαστρεντερίτιδες
- Στη δυσανεξία στην λακτόζη
- Στη στοματική υγεία
- Στην καλή εγκεφαλική λειτουργία – διάθεση
- Σε ένα γερό ανοσοποιητικό σύστημα
- Όταν γίνεται χρήση αντιβιοτικών, όπου καταστρέφεται η ισορροπία της εντερικής χλωρίδας σε βάρος των ‘καλών’ βακτηρίων.
- Στην απορρόφηση θρεπτικών συστατικών από την τροφή
- Στη δυσλειτουργία του πεπτικού συστήματος (διάρροια, δυσκοιλιότητα)
- Στα φλεγμονώδη νοσήματα του εντέρου (νόσος crohn)
- Στους κολικούς
- Στις γαστρεντερίτιδες
- Στη δυσανεξία στην λακτόζη
- Στη στοματική υγεία
- Στην καλή εγκεφαλική λειτουργία – διάθεση
- Σε ένα γερό ανοσοποιητικό σύστημα
- Όταν γίνεται χρήση αντιβιοτικών, όπου καταστρέφεται η ισορροπία της εντερικής χλωρίδας σε βάρος των ‘καλών’ βακτηρίων.
The Food and Agriculture
Organization (FAO) of the United Nations and the World Health
Organization (WHO) define probiotics as “live microorganisms that, when
administered in adequate amounts, confer a health benefit on the host.”1 Probiotics usually include members of the bacteria genera Lactobacillus, Bifidobacterium, Saccharomyces, and Streptococcus.2
The evidence supporting the use of probiotics in pediatrics is
variable, with no fully comprehensive guidelines for probiotic use
available.3-5
As there is no regulatory framework for the manufacturing of
probiotics, preparations differ in the types of bacteria, numbers of
strains, and colony-forming units (CFUs) of microorganisms that they
contain. Additionally, prescriptions are not needed to obtain probiotics
and appropriate dosing recommendations are not well defined for
children or adults, illustrating the need for more well-designed
clinical studies to support their routine use.
Uses of probiotics
Probiotics have been used for many indications, ranging from prevention of antibiotic-associated diarrhea (AAD) to the treatment of inflammatory bowel disease.6 Based on reviews and guidelines from several key working groups, including the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Society for Gastroenterology, Hepatology, and Nutrition (ESPGHAN), and the Latin American Expert Group, the efficacy of probiotics is shown in preventing AAD, severe recurrent Clostridium difficile-associated diarrhea (CDAD), and mild-to-moderate acute diarrhea, mainly with Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii (Table).4,5,7,8
Although a recent meta-analysis of 17 randomized controlled trials (RCTs; n=3953) demonstrated that children receiving probiotics (majority of studies evaluated Lactobacillus and Bifidobacterium spp. at ≥108 cfu/mL) had a 29% risk reduction (95% confidence interval [CI]: 0.54-0.94) of being prescribed antibiotics compared with those who received placebo,9 additional studies are needed to substantiate these findings.
Some other uses of probiotics in children include the treatment of travelers’ diarrhea and acute infectious diarrhea; irritable bowel syndrome (IBS); constipation; infantile colic; necrotizing enterocolitis (NEC); and Helicobacter pylori infection.6 Probiotics may be beneficial in maintaining remission in ulcerative colitis (UC), reducing the risk of NEC in premature infants, and improving
Uses of probiotics
Probiotics have been used for many indications, ranging from prevention of antibiotic-associated diarrhea (AAD) to the treatment of inflammatory bowel disease.6 Based on reviews and guidelines from several key working groups, including the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Society for Gastroenterology, Hepatology, and Nutrition (ESPGHAN), and the Latin American Expert Group, the efficacy of probiotics is shown in preventing AAD, severe recurrent Clostridium difficile-associated diarrhea (CDAD), and mild-to-moderate acute diarrhea, mainly with Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii (Table).4,5,7,8
Although a recent meta-analysis of 17 randomized controlled trials (RCTs; n=3953) demonstrated that children receiving probiotics (majority of studies evaluated Lactobacillus and Bifidobacterium spp. at ≥108 cfu/mL) had a 29% risk reduction (95% confidence interval [CI]: 0.54-0.94) of being prescribed antibiotics compared with those who received placebo,9 additional studies are needed to substantiate these findings.
Some other uses of probiotics in children include the treatment of travelers’ diarrhea and acute infectious diarrhea; irritable bowel syndrome (IBS); constipation; infantile colic; necrotizing enterocolitis (NEC); and Helicobacter pylori infection.6 Probiotics may be beneficial in maintaining remission in ulcerative colitis (UC), reducing the risk of NEC in premature infants, and improving
Lately, the use of probiotics also
has extended beyond that of preventing or treating gastrointestinal
conditions. With growing studies that show possible associations of the
gut microbiome with immune development, vaccine responses, and other
conditions such as asthma, eczema, diabetes, and autism spectrum
disorder,10,11 the use of probiotics has been raised by
patients, researchers, and health professionals to attempt to improve
nongastrointestinal-related health outcomes. Patients supplemented with
prebiotics or probiotics have enhanced influenza antibody titers after
vaccination,12 showing promise for the possible use of such
products to improve vaccine efficacy. Whereas there is potential for
probiotics to play a role in therapy, further investigations including
RCTs should be pursued.
The Table provides a summary of selected meta-analyses and individual
studies for probiotic use in various conditions in pediatrics.13-31
Safety and adverse effects
There are limited data on the safety of probiotics in pediatric patients. Cases of serious infections attributed to organisms that may be contaminants of the probiotic product,32 or by breakthrough bacterial infections from the probiotics themselves, have been reported in the literature.33,34 Some experts have proposed major risk factors for infection including prematurity and immunocompromised states, and minor risk factors including the presence of a central venous catheter, impaired intestinal epithelial barrier, administration through jejunostomy tubes, and cardiac valvular disease (Lactobacillus spp. only).32-35 Caution is advised for patients with a single major risk factor or more than 1 minor risk factor.
In December 2014, the US Food and Drug Administration (FDA) issued a warning to healthcare providers about the risk of probiotic use in immunocompromised patients, referring to an example involving a premature infant who developed fatal gastrointestinal mucormycosis from Rhizopus oryzae.32 The infection was attributed to a contaminant in an unopened container of probiotic powder with active ingredients listed as Bifidobacterium lactis and L rhamnosus. This is a reminder that probiotics are dietary supplements not subject to FDA review, and providers wishing to use these products as drugs (eg, to treat, mitigate, cure, or prevent a disease or condition) should submit an Investigational New Drug (IND) application for review. On the other hand, infant formulas with added probiotics are under FDA regulation and must be made in compliance with good manufacturing practices, although probiotics’ proven benefit is unclear with a paucity of robust evidence.36
Whereas there also have been several studies showing that probiotic use has been safe in certain patient populations, such as LGG use in very-low-birth-weight preterm infants,37 interpreting the data on efficacy and safety of probiotics is complicated, especially because of the heterogeneity of probiotic formulations and the wide variety of diseases in which they have been used. Because of the lack of studies evaluating the safety and efficacy of probiotic use in immunocompromised children, current recommendations do not recommend the use of probiotics for the prevention of C difficile infection in pediatric patients with cancer or hematopoietic stem cell transplants.38
Conclusion
Several studies suggest the beneficial use of probiotics in some circumstances. However, there is insufficient evidence for recommendations on the routine use of probiotics in children.3 As the probiotics industry continues to grow, consistent global regulations, more well-designed human studies, and better safety data are needed to clarify the benefits of probiotics.
Safety and adverse effects
There are limited data on the safety of probiotics in pediatric patients. Cases of serious infections attributed to organisms that may be contaminants of the probiotic product,32 or by breakthrough bacterial infections from the probiotics themselves, have been reported in the literature.33,34 Some experts have proposed major risk factors for infection including prematurity and immunocompromised states, and minor risk factors including the presence of a central venous catheter, impaired intestinal epithelial barrier, administration through jejunostomy tubes, and cardiac valvular disease (Lactobacillus spp. only).32-35 Caution is advised for patients with a single major risk factor or more than 1 minor risk factor.
In December 2014, the US Food and Drug Administration (FDA) issued a warning to healthcare providers about the risk of probiotic use in immunocompromised patients, referring to an example involving a premature infant who developed fatal gastrointestinal mucormycosis from Rhizopus oryzae.32 The infection was attributed to a contaminant in an unopened container of probiotic powder with active ingredients listed as Bifidobacterium lactis and L rhamnosus. This is a reminder that probiotics are dietary supplements not subject to FDA review, and providers wishing to use these products as drugs (eg, to treat, mitigate, cure, or prevent a disease or condition) should submit an Investigational New Drug (IND) application for review. On the other hand, infant formulas with added probiotics are under FDA regulation and must be made in compliance with good manufacturing practices, although probiotics’ proven benefit is unclear with a paucity of robust evidence.36
Whereas there also have been several studies showing that probiotic use has been safe in certain patient populations, such as LGG use in very-low-birth-weight preterm infants,37 interpreting the data on efficacy and safety of probiotics is complicated, especially because of the heterogeneity of probiotic formulations and the wide variety of diseases in which they have been used. Because of the lack of studies evaluating the safety and efficacy of probiotic use in immunocompromised children, current recommendations do not recommend the use of probiotics for the prevention of C difficile infection in pediatric patients with cancer or hematopoietic stem cell transplants.38
Conclusion
Several studies suggest the beneficial use of probiotics in some circumstances. However, there is insufficient evidence for recommendations on the routine use of probiotics in children.3 As the probiotics industry continues to grow, consistent global regulations, more well-designed human studies, and better safety data are needed to clarify the benefits of probiotics.
April 1, 2019 Volume: 36 Issue: 4 Pediatrics
Αυτές οι πληροφορίες προορίζονται για γενική ενημέρωση του κοινού και σε
καμία περίπτωση δεν μπορούν να αντικαταστήσουν τη συμβουλή ιατρού ή
άλλου αρμόδιου επαγγελματία υγείας .
This information is intended as a general guide only and not to provide specific information for individual patient care. Any questions about your own situation should be directed to your medical practitioner. .
Pediamed
This information is intended as a general guide only and not to provide specific information for individual patient care. Any questions about your own situation should be directed to your medical practitioner. .
Pediamed
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου